195 related articles for article (PubMed ID: 19556808)
1. Current oncological treatment of patients with pancreatic cancer in germany: results from a national survey on behalf of the Arbeitsgemeinschaft Internistische Onkologie and the Chirurgische Arbeitsgemeinschaft Onkologie of the Germany Cancer Society.
Boeck S; Bruns CJ; Sargent M; Schafer C; Seufferlein T; Jauch KW; Heinemann V
Oncology; 2009; 77(1):40-8. PubMed ID: 19556808
[TBL] [Abstract][Full Text] [Related]
2. Surgical treatment concepts for patients with pancreatic cancer in Germany--results from a national survey conducted among members of the "Chirurgische Arbeitsgemeinschaft Onkologie" (CAO) and the "Arbeitsgemeinschaft Internistische Onkologie" (AIO) of the Germany Cancer Society (DKG).
Sargent M; Boeck S; Heinemann V; Jauch KW; Seufferlein T; Bruns CJ
Langenbecks Arch Surg; 2011 Feb; 396(2):223-9. PubMed ID: 20711737
[TBL] [Abstract][Full Text] [Related]
3. Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the 'Arbeitsgemeinschaft Internistische Onkologie' (AIO-PK0104).
Heinemann V; Vehling-Kaiser U; Waldschmidt D; Kettner E; Märten A; Winkelmann C; Klein S; Kojouharoff G; Gauler TC; von Weikersthal LF; Clemens MR; Geissler M; Greten TF; Hegewisch-Becker S; Rubanov O; Baake G; Höhler T; Ko YD; Jung A; Neugebauer S; Boeck S
Gut; 2013 May; 62(5):751-9. PubMed ID: 22773551
[TBL] [Abstract][Full Text] [Related]
4. Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer: an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the 'Arbeitsgemeinschaft Internistische Onkologie'.
Boeck S; Vehling-Kaiser U; Waldschmidt D; Kettner E; Märten A; Winkelmann C; Klein S; Kojouharoff G; Gauler T; Fischer von Weikersthal L; Clemens MR; Geissler M; Greten TF; Hegewisch-Becker S; Neugebauer S; Heinemann V
Anticancer Drugs; 2010 Jan; 21(1):94-100. PubMed ID: 19770635
[TBL] [Abstract][Full Text] [Related]
5. Human equilibrative nucleoside transporter 1 is not predictive for gemcitabine efficacy in advanced pancreatic cancer: translational results from the AIO-PK0104 phase III study with the clone SP120 rabbit antibody.
Ormanns S; Heinemann V; Raponi M; Isaacson J; Laubender RP; Haas M; Kruger S; Kleespies A; Mann E; Bartosiewicz M; Kirchner T; Boeck S
Eur J Cancer; 2014 Jul; 50(11):1891-9. PubMed ID: 24857044
[TBL] [Abstract][Full Text] [Related]
6. [Efficacy of gemcitabine-based chemotherapy on advanced pancreatic cancer].
Gong JF; Zhang XD; Li J; Di LJ; Jin ML; Shen L
Ai Zheng; 2007 Aug; 26(8):890-4. PubMed ID: 17697554
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: A prospective phase II study of the 'Arbeitsgemeinschaft Internistische Onkologie'.
Haas M; Siveke JT; Schenk M; Lerch MM; Caca K; Freiberg-Richter J; Fischer von Weikersthal L; Kullmann F; Reinacher-Schick A; Fuchs M; Kanzler S; Kunzmann V; Ettrich TJ; Kruger S; Westphalen CB; Held S; Heinemann V; Boeck S
Eur J Cancer; 2018 May; 94():95-103. PubMed ID: 29549862
[TBL] [Abstract][Full Text] [Related]
8. Gemcitabine, oxaliplatin, and capecitabine (GEMOXEL) compared with gemcitabine alone in metastatic pancreatic cancer: a randomized phase II study.
Petrioli R; Roviello G; Fiaschi AI; Laera L; Marrelli D; Roviello F; Francini E
Cancer Chemother Pharmacol; 2015 Apr; 75(4):683-90. PubMed ID: 25618415
[TBL] [Abstract][Full Text] [Related]
9. Gemcitabine, oxaliplatin and weekly high-dose 5-FU as 24-h infusion in chemonaive patients with advanced or metastatic pancreatic adenocarcinoma: a multicenter phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
Wagner AD; Buechner-Steudel P; Wein A; Schmalenberg H; Lindig U; Moehler M; Behrens R; Kleber G; Kuss O; Fleig WE
Ann Oncol; 2007 Jan; 18(1):82-87. PubMed ID: 17030546
[TBL] [Abstract][Full Text] [Related]
10. [Chemotherapy of pancreatic carcinoma].
Lutz MP
Praxis (Bern 1994); 2005 Jun; 94(22):933-5. PubMed ID: 15986638
[TBL] [Abstract][Full Text] [Related]
11. Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Al-Batran SE; Homann N; Pauligk C; Illerhaus G; Martens UM; Stoehlmacher J; Schmalenberg H; Luley KB; Prasnikar N; Egger M; Probst S; Messmann H; Moehler M; Fischbach W; Hartmann JT; Mayer F; Höffkes HG; Koenigsmann M; Arnold D; Kraus TW; Grimm K; Berkhoff S; Post S; Jäger E; Bechstein W; Ronellenfitsch U; Mönig S; Hofheinz RD
JAMA Oncol; 2017 Sep; 3(9):1237-1244. PubMed ID: 28448662
[TBL] [Abstract][Full Text] [Related]
12. Any progress in the management of advanced pancreatic cancer? Highlights from the 45th ASCO annual meeting. Orlando, FL, USA. May 29-June 2, 2009.
Li J; Saif MW
JOP; 2009 Jul; 10(4):361-5. PubMed ID: 19581735
[TBL] [Abstract][Full Text] [Related]
13. Phase 2 trial of induction gemcitabine, oxaliplatin, and cetuximab followed by selective capecitabine-based chemoradiation in patients with borderline resectable or unresectable locally advanced pancreatic cancer.
Esnaola NF; Chaudhary UB; O'Brien P; Garrett-Mayer E; Camp ER; Thomas MB; Cole DJ; Montero AJ; Hoffman BJ; Romagnuolo J; Orwat KP; Marshall DT
Int J Radiat Oncol Biol Phys; 2014 Mar; 88(4):837-44. PubMed ID: 24606850
[TBL] [Abstract][Full Text] [Related]
14. Prospective phase I study of capecitabine and oxaliplatin concurrent with radiation therapy for the treatment of locally advanced pancreatic adenocarcinoma, and retrospective comparison to concurrent 5-fluorouracil/radiation and gemcitabine/radiation.
Hazard L; Jones K; Shaban A; Anker C; Scaife C; Weis J; Mulvihill S
J Gastrointest Cancer; 2012 Jun; 43(2):258-66. PubMed ID: 21243531
[TBL] [Abstract][Full Text] [Related]
15. Treatment of advanced pancreatic cancer.
Ducreux M; Boige V; Malka D
Semin Oncol; 2007 Apr; 34(2 Suppl 1):S25-30. PubMed ID: 17449349
[TBL] [Abstract][Full Text] [Related]
16. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
[TBL] [Abstract][Full Text] [Related]
17. Metastatic Pancreatic Adenocarcinoma Treatment Patterns, Health Care Resource Use, and Outcomes in France and the United Kingdom Between 2009 and 2012: A Retrospective Study.
Smyth EN; Bapat B; Ball DE; André T; Kaye JA
Clin Ther; 2015 Jun; 37(6):1301-16. PubMed ID: 25907619
[TBL] [Abstract][Full Text] [Related]
18. Gemcitabine versus FOLFIRINOX in patients with advanced pancreatic adenocarcinoma hENT1-positive: everything was not too bad back when everything seemed worse.
Orlandi A; Calegari MA; Martini M; Cocomazzi A; Bagalà C; Indellicati G; Zurlo V; Basso M; Cassano A; Larocca LM; Barone C
Clin Transl Oncol; 2016 Oct; 18(10):988-95. PubMed ID: 26742940
[TBL] [Abstract][Full Text] [Related]
19. [Treatments of pancreatic cancer from the standpoint of medical oncology].
Furuse J; Ishii H; Nakachi K; Suzuki E; Shimizu S
Gan To Kagaku Ryoho; 2007 Jul; 34(7):997-1001. PubMed ID: 17637534
[TBL] [Abstract][Full Text] [Related]
20. Induction Chemotherapy Followed by Concurrent Full-dose Gemcitabine and Intensity-modulated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma.
Badiyan SN; Olsen JR; Lee AY; Yano M; Menias CO; Khwaja S; Wang-Gillam A; Strasberg SM; Hawkins WG; Linehan DC; Myerson RJ; Parikh PJ
Am J Clin Oncol; 2016 Feb; 39(1):1-7. PubMed ID: 26132367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
